CLDI

Calidi Biotherapeutics Inc

0.6900

Oct 28 • 8:43 AM ET +0.0300 (4.55%)

Healthcare Biotechnology USA Nano AMEX

Oct 27, 8:06 AMCalidi Biotherapeutics reports CLD-401 virotherapy eradicated tumors in 80% of mice in preclinical ESMO 2026 data

Peers: GNLX TOVX ONCY CADL REPL IMNN GOVX GNPX AIM INDP

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	2.54M
Enterprise Value	0.19M
Income	-23.45M
Sales	0.00M
Book/sh	1.50
Cash/sh	1.17
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	29
IPO	Nov 01, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.46
P/C	0.59
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.68
Current Ratio	1.68
Debt/Eq	0.62
LT Debt/Eq	0.25
Option/Short	No / Yes

EPS (ttm)	-54.07
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	74.50% -
Sales past 3/5Y	- -
EPS Y/Y TTM	53.95%
Sales Y/Y TTM	-
EPS Q/Q	90.76%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	- -

Insider Own	0.87%
Insider Trans	0.00%
Inst Own	0.82%
Inst Trans	-3.94%
ROA	-283.36%
ROE	-957.93%
ROIC	-601.56%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-20.45%
SMA50	-37.12%
SMA200	-85.28%
Trades

Shs Outstand	3.68M
Shs Float	3.64M
Short Float	4.51%
Short Ratio	1.12
Short Interest	0.16M
52W High	27.04 -97.45%
52W Low	0.62 11.29%
Volatility	10.55% 7.38%
ATR (14)	0.08
RSI (14)	25.15
Beta	1.33
Rel Volume	1.15
Avg Volume	146.07K
Volume	8,401

Perf Week	-10.16%
Perf Month	-36.11%
Perf Quarter	-53.78%
Perf Half Y	-79.33%
Perf YTD	-96.31%
Perf Year	-97.16%
Perf 3Y	-99.98%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	1920.00
Prev Close	0.66
Price	0.69
Change %	4.55%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-23	Initiated	H.C. Wainwright	Buy	$11
Oct-09-23	Initiated	Robert W. Baird	Outperform	$9

Oct-27-26 08:00AM	Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories (GlobeNewswire)
Oct-19-26 08:00AM	Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026 (GlobeNewswire) -6.40%
Sep-25-26 05:00PM	Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency (GlobeNewswire) -5.83% -5.31%
Sep-17-26 09:10AM	Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering (GlobeNewswire) +8.55%
Sep-08-26 08:00AM	Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
04:30PM	Loading…
Aug-13-26 04:30PM	Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -5.52%
Jul-27-26 08:00AM	Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference (GlobeNewswire) +9.50%
Jul-21-26 08:00AM	Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers (GlobeNewswire) -13.93%
Jul-20-26 04:30PM	Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 (GlobeNewswire)
Jul-08-26 04:05PM	Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) +5.35%
Jun-24-26 08:00AM	Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit (GlobeNewswire)
Jun-23-26 08:00AM	Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors (GlobeNewswire)
Jun-16-26 08:00AM	Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study (GlobeNewswire)
Jun-08-26 08:00AM	Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 (GlobeNewswire)
May-26-26 08:00AM	Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting (GlobeNewswire)
06:00PM	Loading…
May-22-26 06:00PM	Calidi Biotherapeutics Provides Required NYSE American Disclosure (GlobeNewswire) -8.39%
May-14-26 04:10PM	Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights (GlobeNewswire) -5.05%
May-13-26 08:00AM	Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston (GlobeNewswire) +8.11%
Apr-29-26 08:00AM	Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI (GlobeNewswire) -6.88%
Apr-21-26 08:00AM	Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 (GlobeNewswire) -11.35%
Apr-20-26 08:00AM	Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 (GlobeNewswire) -9.02%
Apr-15-26 08:00AM	Calidi Biotherapeutics Announces Participation in RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms (GlobeNewswire)
Apr-14-26 08:00AM	Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavik, Iceland on April 28th Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy (GlobeNewswire)
Apr-07-26 08:00AM	Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy (GlobeNewswire)
Apr-02-26 08:00AM	Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 (GlobeNewswire)
Apr-01-26 08:00AM	Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 (GlobeNewswire)
Mar-27-26 04:25PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights (GlobeNewswire) -11.67%
Mar-24-26 08:00AM	Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials (GlobeNewswire)
Mar-12-26 08:00AM	Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing (GlobeNewswire)
Mar-09-26 08:50PM	Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option (GlobeNewswire)
08:30AM	Loading…
Mar-06-26 08:30AM	Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering (GlobeNewswire) -53.14%
02:15AM	Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours - Here's Why (Benzinga)
Mar-05-26 05:57PM	Calidi Biotherapeutics Announces Proposed Public Offering (GlobeNewswire)
Feb-20-26 08:00AM	Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference (GlobeNewswire) +7.97%
Feb-12-26 08:00AM	Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference (GlobeNewswire) -6.89%
Jan-28-26 08:00AM	Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026 (GlobeNewswire)
Nov-17-25 08:00AM	Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025 (GlobeNewswire)
Nov-13-25 04:15PM	Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights (GlobeNewswire)
Nov-10-25 08:00AM	Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC (GlobeNewswire)
Nov-04-25 08:00AM	Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting (GlobeNewswire)
Oct-30-25 08:00AM	Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting (GlobeNewswire) +6.04%
Oct-22-25 08:00AM	Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine (GlobeNewswire) -5.26%
Sep-29-25 08:00AM	Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston (GlobeNewswire)
Sep-02-25 08:00AM	Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-21-25 06:33PM	Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option (GlobeNewswire)
Aug-20-25 09:15AM	Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering (GlobeNewswire) -42.67%
Aug-08-25 04:15PM	Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights (GlobeNewswire) -13.02%
Aug-01-25 11:23AM	Titan of Industry Allan Camaisa Teams Up with Res Nova Bio to Advance Breast Cancer Immunotherapy (PR Newswire)
Jul-29-25 08:00AM	Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma (GlobeNewswire) +14.94%
Jul-25-25 04:45PM	Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 (GlobeNewswire) -5.43% -24.71%
Jul-22-25 08:00AM	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24 (GlobeNewswire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire) +42.57%
08:30AM	Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment (GlobeNewswire)
Jul-09-25 02:01PM	Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds (GlobeNewswire) +108.96%
Jul-08-25 08:30AM	Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment (GlobeNewswire) +39.47%
Jun-27-25 08:00AM	Calidi Biotherapeutics Announces Shareholder Letter from CEO (GlobeNewswire)
Jun-02-25 08:00AM	Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting (GlobeNewswire)
May-16-25 09:55AM	Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-14-25 04:30PM	Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights (GlobeNewswire) -8.47%
Apr-28-25 08:00AM	Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting (GlobeNewswire)
Apr-25-25 08:00AM	Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
Apr-23-25 08:00AM	Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director (GlobeNewswire)
Apr-22-25 08:00AM	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 (GlobeNewswire) +6.59%
Apr-17-25 08:00AM	Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors (GlobeNewswire)
Apr-10-25 08:00AM	Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor (GlobeNewswire)
Mar-31-25 04:30PM	Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -12.89%
04:10PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights (GlobeNewswire)
Mar-28-25 09:00AM	Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -6.53%
Mar-26-25 08:00AM	Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma (GlobeNewswire)
Mar-14-25 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +9.25%
Mar-11-25 02:00PM	IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform (NewMediaWire)
Mar-10-25 08:00AM	Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform (GlobeNewswire) -7.07%
Feb-28-25 09:00AM	Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +5.56%
Feb-24-25 08:00AM	Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital (GlobeNewswire) -7.52%
Jan-29-25 08:00AM	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 (GlobeNewswire)
Jan-28-25 08:00AM	Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement (GlobeNewswire)
Jan-13-25 08:00AM	Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025 (GlobeNewswire)
Jan-10-25 04:30PM	Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock (GlobeNewswire) -32.22%
08:30AM	Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock (GlobeNewswire)
Jan-08-25 04:01PM	Calidi Biotherapeutics Announces Proposed Public Offering (GlobeNewswire) -8.16%
Nov-18-24 08:00AM	Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer (GlobeNewswire) +7.31%
Nov-15-24 04:05PM	Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock (GlobeNewswire) +8.96%
Nov-14-24 08:30AM	Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock (GlobeNewswire) -40.53%
Nov-13-24 04:33PM	Calidi Biotherapeutics Announces Proposed Public Offering (GlobeNewswire) +60.19%
Nov-12-24 05:29PM	Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) +26.35%
Oct-25-24 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +29.76%
Oct-24-24 08:35AM	Calidi to sell 2.05M shares at $1.00 in registered direct offering (TipRanks)
08:30AM	Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences (GlobeNewswire)
Oct-23-24 08:31AM	Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -26.54%
Oct-19-24 05:48PM	Calidi Biotherapeutics Faces Warrant Delisting by NYSE (TipRanks)
Oct-18-24 11:00PM	NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) (GlobeNewswire) -7.38%
08:45AM	Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Sep-30-24 08:00AM	Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma (GlobeNewswire) -5.79%
Aug-13-24 05:37PM	Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -5.71%
Aug-02-24 09:00AM	GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -8.38%
Jul-29-24 09:00AM	Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor (GlobeNewswire)
Jul-18-24 08:00AM	Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform (GlobeNewswire) -8.43%
Jul-16-24 08:00AM	Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board (GlobeNewswire) +7.42%
Jul-05-24 04:15PM	Calidi to Effect Reverse Stock Split (Business Wire) -18.30%
Jun-27-24 07:00AM	Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Camaisa Allan	Director	Dec 12 '25	Sale	1.46	850	1,237	76,952	Dec 16 07:37 PM

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.

CEO & DirectorDr. Eric E. Poma Ph.D.

CFO & Corporate SecretaryMr. Andrew C. Jackson

Pharm.D.Dr. Antonio Fernandez Santidrian Ph.D.

Chief Medical OfficerDr. Guy Travis Clifton M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDI

Calidi Biotherapeutics Inc

Upgrade your Finviz experience